Bladder cancer is the fifth most common in incidence and one of the most expensive cancers to treat. Early detection greatly improves the chances of survival and bladder preservation. The pH Low Insertion Peptide (pHLIP® peptide) conjugated with a near infrared fluorescent dye (ICG) targets low extracellular pH allowing visualization of malignant lesions in human bladder carcinoma ex vivo. Cystectomy specimens obtained after radical surgery were immediately irrigated with non-buffered saline and instilled with a solution of the ICG pHLIP® construct, incubated, and rinsed. Bladders were subsequently opened and imaged, the fluorescent spots were marked, and a standard pathological analysis was carried out to establish the correlation between ICG pHLIP® imaging and white light pathological assessment. Accurate targeting of bladder lesions was achieved with a sensitivity of 97%. Specificity is 100%, but reduced to 80%, if targeting of necrotic tissue from previous transurethral resections or chemotherapy are considered as false positives. ICG pHLIP® imaging agent marked high grade urothelial carcinomas, both muscle invasive and non-muscle invasive. Carcinoma in situ (CIS) was accurately diagnosed in 11 cases, whereas only 4 cases were seen using white light, so imaging with the ICG pHLIP® peptide offers improved early diagnosis of bladder cancers, and may also enable new treatment alternatives. 
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Significance Statement
Bladder cancer is the fifth most common cancer. Timely diagnosis and appropriate early management protocols are of paramount significance for improving patient outcomes. This is the first study to show efficient pH dependent near infrared imaging of bladder malignant tumors without targeting of normal tissue. Our results demonstrate that the ICG pHLIP® construct is suitable for use as a predictive clinical marker, specifically staining human bladder tumors after intravesical administration ex vivo. The targeting allows delivery of various imaging probes, which may offer early diagnosis and improve the outcomes of endoscopic and radical surgical resection of urothelial carcinomas. In addition; delivery of therapeutic molecules to cancer cells by pHLIP® might open an opportunity for novel targeted treatment of bladder cancers.
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Introduction
Bladder cancer is the fifth most common cancer, constituting 4.5% of all new cancer cases in the USA. 76,960 new cases were estimated in 2016 and the death rate currently expected from bladder cancer is 21% (16, 390) . Approximately 2.4 percent of men and women will be diagnosed with bladder cancer at some point during their lifetime. In 2012, there were an estimated 577,403 individuals living with bladder cancer in the United States. Almost all of these patients require continuous surveillance, and, occasionally, treatments. For all stages combined, the 5-year relative survival rate is 77%. Survival declines to 70% at 10 years and 65% at 15 years after diagnosis. Bladder cancer can be non-muscle or muscle invasive. Half of all bladder cancer patients are diagnosed while the tumor is non-muscle invasive, for which the 5-year survival is 96%. Most (up to 98%) of malignant bladder tumors arise in the epithelium, 90-92% of these bladder cancers are urothelial carcinomas (1, 2) . Less common bladder cancers are squamous cell or adenocarcinomas. Approximately 20-25% of patients have muscle invasive disease, and of non-muscle invasive disease patients will progress to muscle invasive disease at 5 years follow up depending on intermediate or high risk of the progression (3, 4) . An important medical objective is the identification of early stage lesions, such as carcinoma in situ, since it is expected that diagnosis at this stage will decrease the frequency of treatments, increasing patient health and reducing expense.
Each type and stage of bladder cancer requires a different type of treatment. High recurrence frequency, procedural costs, and the requirement for prolonged active monitoring, make bladder cancer one of the most expensive cancers in the US, placing a heavy economic burden on the healthcare system from lifetime endoscopic follow ups and treatments. Patients suffer from high morbidity and the complications associated with chemotherapy, radiation and radical surgery (5) . Therefore, as noted, timely diagnosis of the tumor and appropriate management protocols are of great significance for decreasing treatment cost and improving a patient's life style. Advances in the early detection of bladder cancer lesions are likely to increase the chances of timely successful treatment, the prevention of recurrences, and bladder function preservation.
Cancers, including urothelial carcinoma, are associated with multiple alterations in the genome, including changes in epigenetic regulation, point mutations, gene deletions, duplications and chromosomal rearrangements. These changes are heterogeneous, leading to heterogeneity of the overexpression of particular biomarkers at the surfaces of cancer cells within a tumor and between tumors. Heterogeneity significantly limits success in the use of cell surface biomarkers for the targeted delivery of therapeutics. On other hand, multiple studies have revealed that neoplastic cells produce an acidic environment due to increased metabolic activity (6) .
Adaptations to the highly acidic microenvironment are critical steps in the transition from an avascular pre-invasive tumor to a malignant invasive carcinoma (7) (8) (9) . Thus, acidity may provide a universal biomarker for tumor targeting that is not subject to the selection of resistant cell lines (10) . pH Low Insertion Peptides (pHLIP® peptides) are a class of membrane-binding peptides that specifically target acidic cells in vitro and in vivo (11) by inserting across cellular membranes when the extracellular pH is low (12) . pHLIP® peptides conjugated with fluorescent dyes have been used to differentiate normal from neoplastic tissue in various animal tumor models (12) (13) (14) (15) , and in human biopsy head and neck samples (16, 17) . This report is the first study using an ICG pHLIP® conjugate for the diagnosis of urothelial carcinoma and precancerous lesions in fresh human radical cystectomy samples ex vivo, and points the way toward a wide range of diagnostic and therapeutic alternatives.
Results
We used a pHLIP® peptide labeled with a near-infrared fluorescence (NIRF) dye, ICG, to monitor the targeting of tumors in human bladders. The absorption spectrum of ICG pHLIP® is shown in only the ICG-Cys dye alone was used for instillation (at concentrations from 8 to 40 M in an 80 ml volume), and no specific tumor targeting was observed.
The tabular results of the sensitivity/specificity tests are shown in Tables 2-3 . The test was performed for cancerous versus normal tissue excluding targeting of necrotic and previously treated tissue (Tables 2a and 2b ). The sensitivity and specificity of targeting of cancerous tissue versus normal were found to be 97% and 100%, respectively. If targeting of necrotic tissue from prior post trans-urethral removal of bladder tumors and previously treated (chemotherapy) necrotic tumors by ICG pHLIP® is considered as a false positive, the specificity is reduced from 100% to 80% (Tables 3a and 3b ).
Discussion
We used an ICG pHLIP  construct to target urothelial carcinoma in human bladder specimens (21) . Thus, our goal was to selectively promote increased acidity at cancer cell surfaces to enhance pHLIP® peptide insertion and targeting, while not affecting normal cells with normal metabolism.
In our study we had a mixture of different subtypes of urothelial carcinoma, as expected given that the disease had advanced to the point where the bladder had to be removed. Our cases included typical high grade urothelial carcinoma but also had different variants with prominent squamous cell differentiation, micropapillary urothelial carcinoma, adenocarcinoma and plasmacytoid morphology. It appears that the sensitivity (97%) and specificity (100%) of tumor targeting by ICG pHLIP  peptide is irrelevant to the subtype of tumor. Half of the cystectomy specimens in our study revealed evidence of necrosis and effects from prior treatments, and all revealed evidence of residual tumor (invasive or in-situ) adjacent and associated with necrosis, which was targeted by ICG pHLIP  peptide, possibly from entrapment or uptake of ICG by necrotic areas. Our previous studies did not show targeting of necrotic tissue by pHLIP  peptides in animal tumor models (14) . If targeting of necrotic and previously treated tissues are considered as false positives, the specificity is decreased to 80%, but no false positives were seen for unperturbed lesions. by ICG absorption at 800 nm, ε 800 =137,000 M -1 cm −1 . The purity of the constructs was performed by analytical HPLC and SELDI-TOF mass spectrometry, the amount of free dye in the solution was less than 1%.
Materials and Methods
Conjugation of ICG with the pHLIP
Liposome Preparation
Large unilamellar vesicles were prepared by extrusion. 2.5 mg POPC (1-palmitoyl-2-oleoylsnglycero-3-phosphocholine, Avanti Polar Lipids, Inc.) lipids were dissolved in 0.5 ml chloroform, desolvated on a rotary evaporator and dried under high vacuum for 3 hours. The phospholipid film was then rehydrated in pH 7.4 PBS containing 10 mM D-glucose, vortexed for 5 minutes, and repeatedly extruded at least 15 times through a membrane with a 100 nm pore size.
Absorption and Fluorescence Measurements
Absorbance and fluorescence measurements were carried out on a Genesys 10S UV-Vis spectrophotometer (Thermo Scientific) and a SpectraMax M2 spectrofluorometer (Molecular Devices), respectively. The absorption spectra were measured in PBS pH 7. 
Ex vivo Imaging of Bladder Specimens
After obtaining institutional review board (IRB) approval, 22 urothelial carcinoma patients that were scheduled for radical cystectomy were selected over a twelve month period and appropriate informed consent was obtained. After radical cystectomy, bladder specimens were immediately removed and irrigated 3 times for 5 min via catheter with non-buffered saline and instilled and incubated with 80 ml of 8 M or 32.8 g/ml (unless otherwise is stated, see notes to Table 1 ) of ICG pHLIP® construct or ICG-Cys in PBS pH 7.4 containing 10 mM D-glucose for 60 minutes. Then, the unbound constructs were removed by rinsing with 80 ml of saline solution 3-5 times, the bladder was irrigated thoroughly with buffered saline and opened using a Y incision on the anterior wall. Using a da Vinci Si NIRF imaging system (Firefly R ), ex vivo fluorescent and white light imaging of the entire bladder and its parts was performed. The fluorescent spots were marked and standard pathological analysis was carried out to explore the correlation between appearance of fluorescent signal and cancer lesions.
Pathological Analysis
The specimen was sectioned and submitted after 24 hour fixation in 10% phosphate-buffered formalin according to the standard institutional grossing manual, with emphasis on the marked areas of the bladder. The sections were processed for routine histology into paraffin-embedded blocks. Five micrometer thick tissue sections were obtained and stained for hematoxylin and eosin (H&E). Evaluation of pathology was performed by a genitourinary (GU) pathologist, and a standard report was prepared based on the American Joint Committee on Cancer (AJCC) Cancer
Staging Manual, 7 th edition, 2010.
Statistical Analysis
Statistical parameters were calculated according to the following equations:
Where TP is the true positive; TN is the true negative; FP is the false positive; FN is the false negative; TRP is the true positive rate or sensitivity; SPC is the true negative rate or specificity;
PPV is the positive predictive value or precision; NPV is the negative predictive values; FPR is the false positive rate; FNR is the false negative rate; FDR is the false discovery rate; FOR is the false omission rate. TP is the true positive; TN is the true negative; FP is the false positive; FN is the false negative TP is the true positive; TN is the true negative; FP is the false positive; FN is the false negative 
